Bone/Mineral Metabolism News

Only 1 in 10 men and fewer than 2 in 10 women who did not receive osteoporosis therapy at the time of a fracture were prescribed adequate treatment during follow-up, increasing secondary fracture risks for those left untreated, according to an analysis of data from Austria published in Bone.

The FDA on Monday approved an osteoporosis medication — PF708 — developed by Pfenex under the 505(b)(2) regulatory pathway as a follow-on biologic to teriparatide injection, according to a press release from the company.

SAN DIEGO — Understanding which drugs and drug classes contribute to adverse bone effects, including bone loss and fractures, may be extremely useful for rheumatologists and their patients, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

Older adults who sustain a hip or vertebral fracture should be appropriately evaluated and treated for osteoporosis to reduce the risk for secondary fracture, with clinicians utilizing fracture liaison services and offering pharmacotherapy, according to a consensus statement published in the Journal of Bone and Mineral Research.

Among a cohort of postmenopausal women randomly assigned to romosozumab or alendronate, larger improvements in bone mineral density and bone strength in the lumbar spine were observed for those taking romosozumab, according to findings presented at the American Society of Bone and Mineral Research annual meeting.

Bone mineral content and density improved following a resistance training program included with school-based physical education for middle school girls, and these results largely held in subsequent years, according to findings presented at the American Society of Bone and Mineral Research annual meeting.

Daily vitamin D supplementation does not influence the progression of arterial calcification or increase the likelihood that the condition will develop, according to findings presented at the American Society of Bone and Mineral Research annual meeting.

Researchers identified metabolic signatures in baby teeth that were unique to ADHD, autism spectrum disorder and both neurodevelopment conditions, according to a study published in Translational Psychiatry.

Postmenopausal women who took denosumab for a year did experienced no significant decrease in bone mineral density after switching to alendronate, according to findings presented at the American Society of Bone and Mineral Research annual meeting.

Debate continues among endocrinologists regarding what constitutes the “optimal” level of vitamin D, and dozens of studies have assessed the benefits of vitamin D supplementation on everything from fracture risk to diabetes and autoimmune disease. Most recently, the large-scale VITAL trial, presented in November at the American Heart Association Scientific Sessions, suggested the supplement failed to prevent major cardiovascular events and the development of invasive cancers over 5 years, although a deeper dive into the findings reveals a signal for benefits with vitamin D for certain subsets of patients.